Last reviewed · How we verify
NCT02768324
the Effect of Gut Microbiota on the Prognosis of Sepsis
trial in Sepsis in 30 participants. Status unknown.
1 December 2018
Quick facts
| Lead sponsor | Jinan University Guangzhou |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 May 2017 |
| Primary completion | 1 December 2018 |
| Estimated completion | 1 September 2019 |
Conditions studied
- Sepsis — all drugs for Sepsis →
Sponsor
Jinan University Guangzhou
Who can join
Adults 18 to 65, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sepsis is a life-threatening condition that arises when the body's response to infection injures its own tissues and organs. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion. Clinically, sepsis patients with diarrhea often result in a bad prognosis. Gut microbiota consists of a complex community of microorganisms that live in the digestive tracts of animals. The gut microbiota comprises the largest and most diverse reservoir of mutualistic microorganisms associated with animals. The aims of this study is to determin the effect of gut microbiota on the prognosis of Sepsis, by using 16s pyrosequencing, comparing the blood culture result.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Challenge to the Intestinal Mucosa During Sepsis.
Haussner F, Chakraborty S, Halbgebauer R, Huber-Lang M. · · 2019 · cited 141× · PMID 31114571 · DOI 10.3389/fimmu.2019.00891
Verify or expand the search:
- PubMed search for NCT02768324
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other Jinan University Guangzhou trials
Trials by the same sponsor.
- NCT07341633 — AI-Based Digital Therapeutics vs. Traditional Schroth Exercises for Adolescent Idiopathic Scoliosis · NA · not yet recruiting
- NCT07338058 — High-Intensity Exercise Snacks for Reducing Mobile Phone Addiction in Adolescents · NA · completed
- NCT07380750 — Active Families, Healthy Minds: A Family-Centered School Physical Activity Program for Early Adolescents · NA · active not recruiting
- NCT07322952 — Gamified Tai Chi Intervention to Improve Executive Function in Children With Autism Spectrum Disorder · NA · active not recruiting
- NCT06795061 — Fitness Buddy Program to Boost Physical Activity in University Students · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02768324 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jinan University Guangzhou
- Last refreshed: 9 March 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02768324.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing